Idera Pharmaceuticals, Inc. IDRA today announced that it has
regained global rights to IMO-2055, an agonist of Toll-like Receptor (TLR) 9,
as part of an agreed-upon termination of its oncology collaboration with Merck
KGaA, Darmstadt, Germany. During the collaboration, Merck KGaA conducted Phase
1 trials of IMO-2055 in several cancer indications and has an ongoing
randomized Phase 2 trial of IMO-2055 in combination with Erbitux^ in patients
with squamous cell cancer of the head and neck. As previously
announced in July 2011, Merck had informed Idera that it would not continue
clinical development of IMO-2055 beyond completing the ongoing Phase 2 trial
in SCCHN.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in